Summary

The addition of lapatinib (L) to capecitabine plus oxaliplatin (Cape/Ox) does not improve overall survival in patients with locally advanced or metastatic gastric, esophageal, or gastroesophageal junction cancer whose tumors have amplification of the HER2 gene, although an improvement in survival was seen in patients of Asian descent and those aged <60 years. Results were presented from the Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer [LOGiC; NCT00680901; J Clin Oncol 2013 (suppl; abstr LBA4001)], which compared Cape/Ox alone or in combination with lapatinib (Cape/Ox/L) as first-line treatment for patients with advanced or metastatic HER2 -positive upper gastrointestinal tract cancers.